Gladstone Institute of Cardiovascular Disease and Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.
Diabetes Center, School of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Cell Stem Cell. 2014 Feb 6;14(2):228-36. doi: 10.1016/j.stem.2014.01.006.
Pancreatic β cells are of great interest for the treatment of type 1 diabetes. A number of strategies already exist for the generation of β cells, but a general approach for reprogramming nonendodermal cells into β cells could provide an attractive alternative in a variety of contexts. Here, we describe a stepwise method in which pluripotency reprogramming factors were transiently expressed in fibroblasts in conjunction with a unique combination of soluble molecules to generate definitive endoderm-like cells that did not pass through a pluripotent state. These endoderm-like cells were then directed toward pancreatic lineages using further combinations of small molecules in vitro. The resulting pancreatic progenitor-like cells could mature into cells of all three pancreatic lineages in vivo, including functional, insulin-secreting β-like cells that help to ameliorate hyperglycemia. Our findings may therefore provide a useful approach for generating large numbers of functional β cells for disease modeling and, ultimately, cell-based therapy.
胰腺 β 细胞对于 1 型糖尿病的治疗具有重要意义。目前已经有许多生成 β 细胞的策略,但将非内胚层细胞重编程为 β 细胞的通用方法可能在多种情况下提供一种有吸引力的替代方法。在这里,我们描述了一种逐步的方法,即在成纤维细胞中瞬时表达多能性重编程因子,并与独特的可溶性分子组合,生成不经过多能状态的确定性内胚层样细胞。然后,使用进一步的小分子组合在体外将这些内胚层样细胞定向到胰腺谱系。体内生成的胰腺祖细胞样细胞可以成熟为所有三种胰腺谱系的细胞,包括具有功能、能分泌胰岛素的β 样细胞,有助于改善高血糖。因此,我们的研究结果可能为生成大量用于疾病建模和最终基于细胞的治疗的功能性 β 细胞提供一种有用的方法。